View Cart  

Health Canada May Allow Sponsors to Skirt Human Bioavailability Studies

A A
Drug sponsors may be able to avoid establishing in vivo bioequivalence as part of safety and efficacy data requirements in situations where in vitro data provides a reasonable estimate of the relative in vivo performance of the two products, according to a new Health Canada draft guidance.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00